Please login to the form below

Merck and Co/MSD

This page shows the latest Merck and Co/MSD news and features for those working in and with pharma, biotech and healthcare.

AZ’s comeback drug cediranib stumbles in phase 3 trial

The National Cancer Institute-sponsored GY004 study compared cediranib plus AZ and Merck &Co/MSD's leading PARP inhibitor Lynparza (olaparib) against chemo in patients with platinum-sensitive ovarian cancer, but ... and cervical cancer indications,

Latest news

Roche files Tecentriq/Avastin combo in liver cancer

Its combination with Avastin is viewed as a central part of its strategy to gain ground on the leaders in the category, such as Merck &Co/MSD’s Keytruda (pembrolizumab) and ... Tecentriq has carved out a nice for itself in indications including
FDA starts priority review of BMS Opdivo/Yervoy in first-line NSCLC

t have EGFR or ALK mutations, and is due to deliver a verdict by 15 May. ... If approved, BMS will finally have a regimen that can challenge its main rival in the PD-1 inhibitor category – Merck &Co/MSD and its Keytruda (pembrolizumab) product –
FDA starts speedy review of Lynparza plus Avastin in ovarian cancer

AZ/Merck look set to consolidate dominance in this indication. AstraZeneca and Merck &Co/MSD’s PARP inhibitor looks set to consolidate its grip on the ovarian cancer market, after being ... Lynparza has been the dominant drug in the PARP inhibitor
AZ, Merck win FDA approval for Lynparza in pancreatic cancer

New treatment option for subset of patients with BRCA-mutations. AstraZeneca and partner Merck &Co/MSD can now add pancreatic cancer to the growing list of cancers targeted by their PARP ... The approval will help AZ and Merck to maintain a lead over
Lynparza cleared for first-line ovarian cancer use in China

Continues to cement lead in PARP inhibitor category. AstraZeneca and its marketing partner MSD (known as Merck &Co in North America) have scored marketing authorisation in China for their PARP inhibitor ... Although Lynparza has been the lead in the PARP

More from news
Approximately 0 fully matching, plus 53 partially matching documents found.

Latest Intelligence

Can protein degraders unlock ‘undruggable’ drug targets?

like Novartis, Amgen, Pfizer and Merck &Co/MSD. ... which adds to previous collaborations with Roche’s Genentech subsidiary, Pfizer, and also Merck &Co/MSD that committed $434m to the company shortly after it launched in 2013.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Merck KGaA’s Oschmann elected president of IFPMA

He takes over from Lilly’s John Lechleiter. Global pharma trade body the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has elected Merck KGaA's Stefan Oschmann as its new ... His pharma experience includes an 11-year
Merck KGaA shakes up pharma leadership

Johannes Baillou, chairman of the board of partners of Merck, said: “With today's management decisions we strengthen Merck's leadership team and prepare the ground for continuity to reach our ... Oschmann also joined Merck in 2011, having spent the

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Could formulary intelligence be your brand differentiator?: Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
How COVID-19 is accelerating the threat of antimicrobial resistance: Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping: Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...